ENANTA PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ENTA$11.22-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except per share data)
| March 31, | September 30, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $34,928 | $32,298 |
| Short-term marketable securities | 128,846 | 156,566 |
| Accounts receivable | 7,809 | 6,882 |
| Prepaid expenses and other current assets | 6,810 | 8,590 |
| Income tax receivable | 19 | — |
| Total current assets | 178,412 | 204,336 |
| Long-term marketable securities | 63,238 | — |
| Property and equipment, net | 33,114 | 35,395 |
| Operating lease, right-of-use assets | 36,436 | 37,549 |
| Long-term restricted cash | 3,360 | 3,360 |
| Other long-term assets | 144 | 92 |
| Total assets | $314,704 | $280,732 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $4,363 | $1,948 |
| Accrued expenses and other current liabilities | 6,859 | 12,751 |
| Liability related to the sale of future royalties | 31,461 | 30,710 |
| Operating lease liabilities | 3,759 | 3,146 |
| Total current liabilities | 46,442 | 48,555 |
| Liability related to the sale of future royalties, net of current portion | 97,309 | 111,132 |
| Operating lease liabilities, net of current portion | 52,777 | 54,757 |
| Series 1 nonconvertible preferred stock | 1,311 | 1,311 |
| Other long-term liabilities | 278 | 260 |
| Total liabilities | 198,117 | 216,015 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Common stock; $0.01 par value per share, 100,000 shares authorized; 29,061 and 21,387 shares issued and outstanding at March 31, 2026 and September 30, 2025 respectively | 291 | 214 |
| Additional paid-in capital | 546,988 | 469,771 |
| Accumulated other comprehensive loss | (734) | (339) |
| Accumulated deficit | (429,958) | (404,929) |
| Total stockholders' equity | 116,587 | 64,717 |
| Total liabilities and stockholders' equity | $314,704 | $280,732 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.